Skip to content

Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors.

Christian V Cabanlong, Lauren N Russell, William E Fantegrossi, Paul L Prather

Toxicological sciences : an official journal of the Society of Toxicology April 26, 2022 DOI: 10.1093/toxsci/kfac024 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics In vitro and in vivo pharmacology study Peer reviewed
Population Mice (in vivo experiments); CB1 receptor preparations (in vitro)
Interventions 5F-MDMB-PINACA 5F-MDMB-PINACA-M7 Δ9-THC rimonabant
Keywords G-protein coupled receptors Cb1 receptors Metabolites Novel psychoactive substances Synthetic cannabinoids Toxicity
Key points 5F-MDMB-PINACA and its metabolite M2 act as high-efficacy CB1 agonists with nanomolar affinity, while the major metabolite M7 retains high efficacy but only low micromolar affinity. Chronic administration down-regulates CB1 receptors, but only the parent drug desensitizes them. The authors propose that accumulation of active metabolites with atypical pharmacodynamics may contribute to severe toxicity.

Abstract

Synthetic cannabinoid receptor agonists (SCRAs) are a large group of abused psychoactive compounds that elicit numerous toxic effects not observed with cannabis, including death. Abuse of third-generation SCRA 5F-MDMB-PINACA (also known as 5F-ADB) has been associated with over 40 fatalities. This SCRA is metabolized to several active phase I metabolites, including excessively high post-mortem serum concentrations of an ester hydrolysis metabolite, 5F-MDMB-PINACA-M7 (M7). Although high serum concentrations of M7 (and other active metabolites) have been suggested to contribute to 5F-MDMB-PINACA toxicity, the affinity of M7 for CB1 receptors is unknown and more complete pharmacodynamic characterization of 5F-MDMB-PINACA and its active metabolites is needed. Competition binding and G-protein modulation studies presented here confirm reports that 5F-MDMB-PINACA and a second N-5-hydroxypentyl metabolite (M2) exhibit nM affinity and act as high efficacy agonists at CB1 receptors. Also as previously published, M7 exhibits high efficacy at CB1 receptors; however, demonstrated here for the first time, M7 retains only low μΜ affinity. Empirically derived Kb values indicate rimonabant differentially antagonizes G-protein activation produced by 5F-MDMB-PINACA, relative to Δ9-THC (THC) or its metabolites. Chronic administration of 5F-MDMB-PINACA and metabolites results in CB1 down-regulation, but only 5F-MDMB-PINACA produces desensitization. Although low CB1 affinity/potency of M7 precluded in vivo studies, both M2 and THC produce locomotor suppression and CB1-mediated dose-dependent hypothermia and analgesia in mice. Collectively, these data confirm and extend previous studies suggesting that 5F-MDMB-PINACA is metabolized to active compounds exhibiting atypical pharmacodynamic properties at CB1 receptors, that may accumulate with parent drug to produce severe toxicity.

Citations in the library

Explore topics